RRM1 and neoplasm: In multivariate analysis, high RRM1 expression was an independent predictor for poorer tumor response to gemcitabine plus platinum chemotherapy (hazard ratio [HR] 7.68, 95% confidence interval [CI] 1.69 to 34.99, P = 0.008; Table 3).